Nabriva Therapeutics up on promising cystic fibrosis study data
28/11/2022 12:25
** Nabriva Therapeutics Plc shares NBRV.O up 15.2% at $2.5
premarket
** Says experimental drug to treat adult patients with
cystic fibrosis appears to be safe and well-tolerated in
early-stage study urn:newsml:reuters.com:*:nGNX4YhSPz
** Cystic fibrosis is a genetic condition in which a faulty
protein affects the body's cells, tissues, and the glands that
make mucus and sweat - NIH
** Up to Friday close, stock down ~86% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update